Tisdag 17 November | 19:57:31 Europe / Stockholm
Est. tid*
2026-11-13 - Kvartalsrapport 2026-Q3
2026-08-27 - Kvartalsrapport 2026-Q2
2026-05-21 - Kvartalsrapport 2026-Q1
2026-04-15 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2026-04-14 - Årsstämma
2026-02-12 - Bokslutskommuniké 2025
2026-01-26 - Extra Bolagsstämma 2026
2025-11-18 - Kvartalsrapport 2025-Q3
2025-08-28 - Kvartalsrapport 2025-Q2
2025-05-15 - Kvartalsrapport 2025-Q1
2025-04-30 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2025-04-29 - Årsstämma
2025-02-13 - Bokslutskommuniké 2024
2024-11-19 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-04-25 - Extra Bolagsstämma 2024
2024-04-19 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2024-04-18 - Årsstämma
2024-02-29 - Bokslutskommuniké 2023
2023-11-09 - Kvartalsrapport 2023-Q3
2023-08-31 - Kvartalsrapport 2023-Q2
2023-05-11 - Kvartalsrapport 2023-Q1
2023-04-19 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2023-04-18 - Årsstämma
2023-02-16 - Bokslutskommuniké 2022
2022-11-17 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-12 - Kvartalsrapport 2022-Q1
2022-04-22 - X-dag ordinarie utdelning LYTIX 0.00 NOK
2022-04-21 - Årsstämma
2022-02-17 - Bokslutskommuniké 2021
LandNorge
ListaEuronext Growth Oslo
SektorHälsovård
IndustriBioteknik
Lytix Biopharma är ett bioteknikbolag i kliniskt stadium som utvecklar cancerimmunterapier. Bolagets teknik bygger på forskning inom antimikrobiella peptider, ett försvar riktade mot patogener. Lytix Biopharmas huvudprodukt, LTX-315, är en onkolytisk peptid med syftet att personalisera immunterapi. Bolaget bedriver sin forskning och verksamhet i Oslo, Norge.

Analysera bolaget i Börsdata!

All ägardata du vill ha finns i Holdings!

Lytix Biopharma ASA: Contemplated private placement and retail offer via Nordnet

2026-11-17 16:30:48
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART DIRECTLY OR
INDIRECTLY, IN AUSTRALIA, CANADA, JAPAN, HONG KONG, SOUTH AFRICA OR THE UNITED
STATES OR ANY OTHER JURISDICTION IN WHICH THE RELEASE, PUBLICATION OR
DISTRIBUTION WOULD BE UNLAWFUL. THIS ANNOUNCEMENT IS NOT A PROSPECTUS AND DOES
NOT CONSTITUTE A PUBLIC OFFER OF ANY OF THE SECURITIES DESCRIBED HEREIN.

Oslo, 17 November 2026, Lytix Biopharma ASA ("Lytix Biopharma" or the "Company")
has retained DNB Carnegie, a part of DNB Bank ASA, as sole bookrunner (the
"Manager"), to advise on and effect a private placement of new shares raising
NOK 60-80 million in gross proceeds (the "Private Placement"). The Company is
also contemplating to effect an offering of new shares directed at retail
investors in Norway to raise gross proceeds of up to the NOK equivalent of up to
EUR 1 million to be facilitated via Nordnet Bank AB ("Nordnet") and made through
its facilities (the "Retail Offering") (such shares, together with the new
shares in the Private Placement, the "Offer Shares").

The price per share in the Private Placement and the Retail Offering is fixed at
NOK 8.00 per Offer Share (the "Offer Price").

Over the past years, Lytix Biopharma has developed into a more mature and
de-risked clinical-stage company. Ruxotemitide has shown strong clinical results
across several Phase II studies in multiple skin cancer indications. The
Company's key near-term value driver is the potential of ruxotemitide in
neoadjuvant melanoma, i.e. treatment before surgery. It covers a large patient
group with strong commercial prospects, and current treatment options leave
substantial room for improvement. The Phase II NeoLIPA study (ruxotemitide plus
pembrolizumab) recently met its primary endpoint, and a more detailed data set
will be presented as a late-breaking abstract at ESMO IO in London mid-December
2026. The capital raise aims to strengthen the clinical case for ruxotemitide
through the ALETTA study, an investigator-led Phase II study in neoadjuvant
melanoma in combination with ipilimumab and nivolumab, and to fund preparations
for a planned registrational Phase III study in neoadjuvant melanoma.

The net proceeds from the Private Placement and the Retail Offering will be used
for (i) ruxotemitide Phase III readiness - long-lead items that cannot be
deferred without delaying first patient in: protocol finalisation and regulatory
preparations, CRO selection, country and site feasibility, and clinical drug
supply and manufacturing readiness, (ii) ALETTA - the Company's share of costs
for the investigator-led Phase II study, the majority of the study costs being
covered by the sponsor, (iii) LTX-401 - advancing toward Phase I, and (iv)
general corporate purposes and working capital.

The net proceeds will fund Phase III readiness and working capital up to the
decision on whether to initiate the Phase III study, expected in 2027. The Phase
III study itself is not funded by the Private Placement and the Retail Offering,
and will require additional financing and/or partnering before it is initiated.
Based on gross proceeds of NOK 60-80 million, and assuming the Phase III study
is not initiated before such financing is secured, the Company's cash runway is
expected to extend into the fourth quarter of 2027.

The Company has, subject to customary terms and conditions, received
pre-commitments in the Private Placement of approximately NOK 60 million from
the largest existing shareholders in the Company, including:
- Jakob Hatteland Holding AS (NOK 25 million),
- Saturn Invest AS and HIFO Invest AS (NOK 10 million),
- TAJ Holding AS (NOK 18 million), and
- Per Strand Eiendom AS (NOK 7 million).

The Private Placement will be directed towards selected Norwegian and
international investors (a) outside the United States, subject to applicable
exemptions from any prospectus and registration requirements and in reliance on
Regulation S under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and (b) to investors in the United States who are QIBs as defined in Rule
144A under the Securities Act, in each case subject to an exemption being
available from prospectus requirements and any other filing or registration
requirements in the applicable jurisdictions and subject to other selling
restrictions.

The Retail Offering comprises a retail offer of the NOK equivalent of up to EUR
1 million to the public in Norway, subject to an exemption being available from
prospectus requirements and any other filing or registration requirements in the
applicable jurisdictions and subject to other selling restrictions. In the
Retail Offering, the maximum allocation amount to Norwegian investors is the NOK
equivalent of EUR 1 million.

Applications

The application period for the Private Placement opens today at 16:30 CET and
closes on 18 November 2026 at 08:00 CET. The application period for the Retail
Offering will commence today, 17 November 2026, at 16:45 CET and closes at 21:00
CET on 17 November 2026 (such period, together with the application period for
the Private Placement, the "Application Periods"). The Company reserves the
right to shorten, close or extend the Application Periods at any time and for
any reason on short notice or without notice. If the Application Periods are
shortened or extended, the other dates referred to herein may be changed
accordingly.

The minimum order size and allocation in the Private Placement will be the NOK
equivalent of EUR 100,000, provided that the Company may, at its sole
discretion, allocate Offer Shares for an amount below the NOK equivalent of EUR
100,000 to the extent applicable exemptions from relevant prospectus
requirements are available. Further selling restrictions and transaction terms
will apply. The Private Placement is for the avoidance of doubt solely directed
towards investors subject to, and in compliance with, applicable exemptions from
relevant prospectus or registration requirements.

Applications in the Retail Offering can be made through the website of Nordnet
from commencement of the application period for the Retail Offering, and must be
made before the end of the application period for the Retail Offering.

Allocation, conditionality and settlement

Allocation of Offer Shares will be made at the sole discretion of the Company's
board of directors (the "Board") in consultation with the Manager after expiry
of the Application Periods (subject to any shortening or extension), who will
focus on criteria such as (but not limited to) pre-commitments, perceived
investor quality, existing ownership in the Company, timeliness of the
application, early indication, relative order size, sector knowledge, investment
history and investment horizon. The Board may, at its sole discretion, reject
and/or reduce any applications. There is no guarantee that any applicant will be
allocated Offer Shares, other than the pre-committed investors. Notifications of
allocations are expected to be distributed to applicants on or about 18 November
2026.

The Retail Offering is incidental to the Private Placement and will in any case
be limited to a maximum of the NOK equivalent of EUR 1 million. Allocations may
be reduced at the Company's discretion, should demand exceed this limit. In any
event, completion of the Retail Offering is conditional upon completion of the
Private Placement, and the Retail Offering will not be carried out if the
Private Placement does not occur. The Private Placement is, however, not
conditional on the Retail Offering. Within the framework of the Retail Offering,
investors may only subscribe via the website of Nordnet.

Completion of the Private Placement is subject to (i) all necessary resolutions
required to implement the Private Placement being validly made by the Company,
including the Board resolving to complete the Private Placement, allocate the
Offer Shares and issue the Offer Shares pursuant to the Board Authorisation (as
defined below), (ii) the Share Lending Agreement (as defined below) remaining
unmodified and in full force and effect, and (iii) the timely delivery of the
shares to be borrowed under the Share Lending Agreement for settlement of the
Private Placement and Retail Offering. The Company, in consultation with the
Manager, reserves the right, at any time and for any reason, to cancel, and/or
modify the terms of, the Private Placement and the Retail Offering. Neither the
Manager nor the Company will be liable for any losses if the Private Placement
and/or the Retail Offering is cancelled and/or modified, irrespective of the
reason for such cancellation or modification.

Settlement is expected to take place as follows:

Settlement of the Offer Shares in the Private Placement is expected to take
place on 20 November 2026. Settlement of the Offer Shares in the Retail Offering
will take place on the same date, in accordance with the procedures communicated
by Nordnet through its website.

The Offer Shares (including the shares allocated in the Retail Offering) will,
other than for the Share Lenders (as defined below), be settled on a
delivery-versus-payment ("DvP") basis with existing and unencumbered shares in
the Company that are already listed on Euronext Growth Oslo, to be borrowed from
Jakob Hatteland Holding AS, Saturn Invest AS and TAJ Holding AS (in their
capacity as such, the "Share Lenders") by the Manager pursuant to a share
lending agreement entered into between the Manager, the Company and the Share
Lenders (the "Share Lending Agreement"). The share loan, including shares
allocated to the Share Lenders (if any), will be settled with new shares (equal
to the number of Offer Shares) in the Company to be issued by the Board pursuant
to the authorisation granted by the Company's extraordinary general meeting on
26 January 2026 (the "Board Authorisation"). The Offer Shares will be tradeable
from notification of allocation to applicants, expected on or about 18 November
2026.


Lock-ups

The Company and members of the Company's management and Board have entered into
a customary lock-up arrangement with the Manager that, subject to customary
exceptions, will restrict their ability to, without the prior written consent of
the Manager, issue, sell or dispose of shares, as applicable, for a period of 90
days for the Company and 180 days for the members of management and Board after
completion of the Private Placement and Retail Offering.

Potential subsequent repair offering

The Board has considered the structure of the contemplated Private Placement and
Retail Offering in light of the equal treatment obligations under the Norwegian
Public Limited Liability Companies Act and Rule Book II for companies listed on
Euronext Growth Oslo, and is of the opinion that the proposed Private Placement
and Retail Offering are in compliance with these requirements. By structuring
the transaction as a private placement and retail offering pursuant to
applicable exemptions from prospectus filing requirements, the Company will be
in a position to raise capital in an efficient manner with a lower discount to
the current trading price and with significantly lower completion risks compared
to a rights issue. Furthermore, the number of Offer Shares to be issued in
connection with the contemplated Private Placement and Retail Offering implies
that the dilution of existing shareholders will be limited. Finally, the Board
will consider carrying out a subsequent offering directed towards shareholders
who do not participate in the Private Placement or the Retail Offering (see
details below) in order to further limit the dilutive effect of the Private
Placement and the Retail Offering. On this basis and based on an assessment of
the current equity markets, the Board has considered the Private Placement and
Retail Offering to be in the common interest of the Company and its
shareholders. As a consequence of the contemplated transaction structure, the
shareholders' preferential rights to subscribe for the Offer Shares will be set
aside.

Notwithstanding the above, the Company reserves the right, subject to, inter
alia, completion of the Private Placement and depending on the participation of
retail investors in the Retail Offering, to carry out a customary subsequent
offering of new shares at the Offer Price. Any such subsequent offering, if
applicable and subject to applicable securities laws, will be directed towards
existing shareholders in the Company as of 17 November 2026 (as registered in
the VPS two trading days thereafter), who (i) were not included in the
pre-sounding phase of the Private Placement, (ii) were not allocated Offer
Shares in the Private Placement or the Retail Offering, and (iii) are not
resident in a jurisdiction where such offering would be unlawful or would (in
jurisdictions other than Norway) require any prospectus, filing, registration or
similar action. Whether a subsequent offering will be carried out will, among
other things, depend on the result of the Private Placement and the subsequent
development of the Company's share price.

Advisors

DNB Carnegie, a part of DNB Bank ASA, is acting as sole bookrunner (the
"Manager").

Advokatfirmaet Thommessen AS is acting as legal advisor to the Company.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act.

This stock exchange announcement has been published on behalf of the Company by
Gjest Breistein (CFO) on 17 November 2026 at the time set out in this notice.

For further information, please contact:

Gjest Breistein, CFO
gjest.breistein@lytixbiopharma.com
+47 952 60 512

About Lytix Biopharma
Based in Oslo, Norway, Lytix Biopharma is a clinical-stage biotech company with
a highly differentiated oncolytic molecule platform based on world-leading
research in host-defense peptide-derived molecules. Lytix Biopharma's lead
product, ruxotemitide (formerly LTX-315), is a first-in-class oncolytic molecule
representing a new approach to effectively prime durable anti-cancer immunity.
Lytix Biopharma has a pipeline of molecules that work across multiple cancer
indications and treatment settings, both as monotherapy and in combination
therapy. Lytix Biopharma is listed on Euronext Growth Oslo under the ticker
LYTIX.

Important information: This announcement is not and does not form a part of any
offer to sell, or a solicitation of an offer to purchase, any securities of the
Company. Copies of this announcement are not being made and may not be
distributed or sent into any jurisdiction in which such distribution would be
unlawful or would require registration or other measures.

The securities referred to in this announcement have not been and will not be
registered under the U.S. Securities Act of 1933, as amended (the "Securities
Act"), and accordingly may not be offered or sold in the United States absent
registration or an applicable exemption from the registration requirements of
the Securities Act and in accordance with applicable U.S. state securities laws.
The Company does not intend to register any part of the offering in the United
States or to conduct a public offering of securities in the United States. Any
sale in the United States of the securities mentioned in this announcement will
be made solely to "qualified institutional buyers" as defined in Rule 144A under
the Securities Act.

In any EEA Member State, this communication is only addressed to and is only
directed at qualified investors in that Member State within the meaning of the
Prospectus Regulation or other investors who can receive the offer in reliance
on an applicable exemption from the obligation to publish a prospectus, i.e.,
only to investors who can receive the offer without an approved prospectus in
such EEA Member State. The "Prospectus Regulation" means Regulation (EU)
2017/1129, as amended (together with any applicable implementing measures) in
any Member State.

This communication is only being distributed to and is only directed at persons
in the United Kingdom that are (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial
Promotion) Order 2005, as amended (the "Order") or (ii) high net worth entities,
and other persons to whom this announcement may lawfully be communicated,
falling within Article 49(2)(a) to (d) of the Order (all such persons together
being referred to as "relevant persons"), and in each case only in circumstances
falling within Part 1 of Schedule 1 to the Public Offers and Admissions to
Trading Regulations 2024 (the "POATRs"). This communication must not be acted on
or relied on by persons who are not relevant persons. Any investment or
investment activity to which this communication relates is available only for
relevant persons and will be engaged in only with relevant persons. Persons
distributing this communication must satisfy themselves that it is lawful to do
so.

The issue, subscription or purchase of shares or other financial instruments in
the Company is subject to specific legal or regulatory restrictions in certain
jurisdictions. Neither the Company nor the Manager assumes any responsibility in
the event there is a violation by any person of such restrictions. The
distribution of this release may in certain jurisdictions be restricted by law.
Persons into whose possession this release comes should inform themselves about
and observe any such restrictions. Any failure to comply with these restrictions
may constitute a violation of the securities laws of any such jurisdiction.

Matters discussed in this announcement may constitute forward-looking
statements. Forward-looking statements are statements that are not historical
facts and may be identified by words such as "believe", "expect", "anticipate",
"strategy", "intends", "estimate", "will", "may", "continue", "should" and
similar expressions. Any forward-looking statements in this release are based
upon various assumptions, many of which are based, in turn, upon further
assumptions. Such assumptions are inherently subject to significant known and
unknown risks, uncertainties, contingencies and other important factors which
are difficult or impossible to predict. Such risks, uncertainties, contingencies
and other important factors could cause actual events to differ materially from
the expectations expressed or implied in this release by such forward-looking
statements. The Company does not make any guarantee that the assumptions
underlying any forward-looking statements in this announcement are free from
errors nor does it accept any responsibility for the future accuracy of the
opinions expressed in this announcement or any obligation to update or revise
the statements in this announcement to reflect subsequent events. You should not
place undue reliance on any forward-looking statements in this announcement. The
information, opinions and forward-looking statements contained in this
announcement speak only as at its date, and are subject to change without
notice. The Company does not undertake any obligation to review, update,
confirm, or to release publicly any revisions to any forward-looking statements
to reflect events that occur or circumstances that arise in relation to the
content of this announcement.

This announcement is made by, and is the responsibility of, the Company. The
Manager is acting exclusively for the Company and no one else and will not be
responsible to anyone other than the Company for providing the protections
afforded to its clients, or for advice in relation to the contents of this
announcement or any of the matters referred to herein. Neither the Manager nor
any of its affiliates makes any representation as to the accuracy or
completeness of this announcement and none of them accepts any responsibility
for the contents of this announcement or any matters referred to herein.

This announcement is for information purposes only and is not to be relied upon
in substitution for the exercise of independent judgment. It is not intended as
investment advice and under no circumstances is it to be used or considered as
an offer to sell, or a solicitation of an offer to buy any securities or a
recommendation to buy or sell any securities of the Company. The distribution of
this announcement and other information may be restricted by law in certain
jurisdictions. Persons into whose possession this announcement or such other
information should come are required to inform themselves about and to observe
any such restrictions. This announcement is an advertisement and is not a
prospectus for the purposes of the Prospectus Regulation as implemented in any
Member State.
y securities or a\
recommendation to buy or sell any securities of the Company. The distribution of\
this announcement and other information may be restricted by law in certain\
jurisdictions. Persons into whose possession this announcement or such other\
information should come are required to inform themselves about and to observe\
any such restrictions. This announcement is an advertisement and is not a\
prospectus for the purposes of the Prospectus Regulation as implemented in any\
Member State.\